The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation
Open accessAbstract
The cellular level of the tumor suppressor p53 is tightly regulated through induced degradation via the ubiquitin/proteasome system. The ubiquitin ligase Mdm2 plays a pivotal role in stimulating p53 turnover. However, recently additional ubiquitin ligases have been identified that participate in the degradation of the tumor suppressor. Apparently, multiple degradation pathways are employed to ensure proper destruction of p53. Here we show that the chaperone-associated ubiquitin ligase CHIP is able to induce the proteasomal degradation of p53. CHIP-induced degradation was observed for mutant p53, which was previously shown to associate with the chaperones Hsc70 and Hsp90, and for the wild-type form of the tumor suppressor. Our data reveal that mutant and wild-type p53 transiently associate with molecular chaperones and can be diverted onto a degradation pathway through this association.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M., & Levine, A. J. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.531 · Cited by 1,144
Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins
Connell, P., Ballinger, C. A., Jiang, J., Wu, Y., Thompson, L. J., Höhfeld, J., & Patterson, C. (2001) · Nature Cell Biology · doi:10.1038/35050618 · Cited by 997
Self-citationp53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Ballinger, C. A., Connell, P., Wu, Y., Hu, Z., Thompson, L. J., Yin, L.-Y., & Patterson, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.6.4535 · Cited by 943
The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation
Meacham, G. C., Patterson, C., Zhang, W., Younger, J. M., & Cyr, D. M. (2001) · Nature Cell Biology · doi:10.1038/35050509 · Cited by 839
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation
Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 723
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 722
The ubiquitin ligase COP1 is a critical negative regulator of p53
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., O' Rourke, K., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 704
Gannon, J. V., Greaves, R., Iggo, R., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 688
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02316-x · Cited by 677
Hershko, A., Ciechanover, A., & Varshavsky, A. (2000) · Nature Medicine · doi:10.1038/80384 · Cited by 649
CHIP Is a U-box-dependent E3 Ubiquitin Ligase
Jiang, J., Ballinger, C. A., Wu, Y., Dai, Q., Cyr, D. M., Höhfeld, J., & Patterson, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101968200 · Cited by 593
Self-citationFunctions of the MDM2 oncoprotein
Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences CMLS · doi:10.1007/s000180050273 · Cited by 577
CHIP is a chaperone‐dependent E3 ligase that ubiquitylates unfolded protein
Murata, S., Minami, Y., Minami, M., Chiba, T., & Tanaka, K. (2001) · The EMBO Reports · doi:10.1093/embo-reports/kve246 · Cited by 574
Mdm2-Mediated NEDD8 Conjugation of p53 Inhibits Its Transcriptional Activity
Xirodimas, D. P., Saville, M. K., Bourdon, J.-C., Hay, R. T., & Lane, D. P. (2004) · Cell · doi:10.1016/j.cell.2004.06.016 · Cited by 570
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.
Pavletich, N. P., Chambers, K. A., & Pabo, C. O. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2556 · Cited by 521
Molecular chaperones and the stress of oncogenesis
Mosser, D. D., & Morimoto, R. I. (2004) · Oncogene · doi:10.1038/sj.onc.1207529 · Cited by 502
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 476
CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival
Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305838200 · Cited by 469
Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300
Grossman, S. R., Deato, M. E., Brignone, C., Chan, H. M., Kung, A. L., Tagami, H., Nakatani, Y., & Livingston, D. M. (2003) · Science · doi:10.1126/science.1080386 · Cited by 459
Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu
Xu, W., Marcu, M., Yuan, X., Mimnaugh, E., Patterson, C., & Neckers, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202365899 · Cited by 433
Yin Yang 1 Is a Negative Regulator of p53
Sui, G., Affar, E. B., Shi, Y., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P., Calvo, D., Grossman, S. R., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.004 · Cited by 424
Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
Hainaut, P. L., & Milner, J. (1993) · PubMed · Cited by 404
GrpE-like regulation of the Hsc70 chaperone by the anti-apoptotic protein BAG-1
Hohfeld, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6209 · Cited by 393
Demand, J., Alberti, S., Patterson, C., & Höhfeld, J. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00487-0 · Cited by 377
Self-citationHdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
Self-citationCHIP activates HSF1 and confers protection against apoptosis and cellular stress
Dai, Q. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg529 · Cited by 320
Common and divergent peptide binding specificities of hsp70 molecular chaperones.
Fourie, A. M., Sambrook, J. F., & Gething, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43837-9 · Cited by 284
p53 Contains Large Unstructured Regions in its Native State
Bell, S., Klein, C., Müller, L., Hansen, S., & Buchner, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00848-3 · Cited by 275
Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers.
Davidoff, A. M., Iglehart, J. D., & Marks, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3439 · Cited by 272
Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., & Prives, C. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2565 · Cited by 265
Cooperation of molecular chaperones with the ubiquitin/proteasome system
Esser, C., Alberti, S., & Höhfeld, J. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.09.020 · Cited by 245
Self-citationThe N-terminal Domain of p53 is Natively Unfolded
Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., & Buchner, J. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.008 · Cited by 229
Stephen, C. W., & Lane, D. P. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90386-x · Cited by 210
Molecular Chaperone Interactions with Steroid Receptors: an Update
Cheung, J. C. Y., & Smith, D. F. (2000) · Molecular Endocrinology · doi:10.1210/me.14.7.939 · Cited by 207
Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., & Cook, P. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1517 · Cited by 206
NEW EMBO MEMBERS' REVIEW: Hsp70 interactions with the p53 tumour suppressor protein
Zylicz, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4634 · Cited by 192
Alberti, S., Demand, J., Esser, C., Emmerich, N., Schild, H., & Höhfeld, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204196200 · Cited by 190
Self-citationXu, Y., Singer, M. A., & Lindquist, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.109 · Cited by 184
Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization
Peng, Y., Chen, L., Li, C., Lu, W., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102817200 · Cited by 183
Alberti, S., Böhse, K., Arndt, V., Schmitz, A., & Höhfeld, J. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-04-0293 · Cited by 179
Self-citationGeldanamycin selectively destabilizes and conformationally alters mutated p53.
Blagosklonny, M. V., Toretsky, J. A., & Neckers, L. (1995) · PubMed · Cited by 178
King, F. W. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6297 · Cited by 167
Hsp90 Regulates the Activity of Wild Type p53 under Physiological and Elevated Temperatures
Müller, L., Schaupp, A., Walerych, D., Wegele, H., & Büchner, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407687200 · Cited by 157
Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein
Walerych, D., Kudla, G., Gutkowska, M., Wawrzynów, B., Muller, L., King, F. W., Helwak, A., Boros, J., Żylicz, M., & Żylicz, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407601200 · Cited by 155
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90
Rüdiger, S., Freund, S. M. V., Veprintsev, D. B., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132393699 · Cited by 100
Milner, J., & Jv, W. (1990) · PubMed · Cited by 96
HSP70 Binding Sites in the Tumor Suppressor Protein p53
Fourie, A. M., Hupp, T. R., Lane, D. P., Sang, B., Barbosa, M. S., Sambrook, J., & Gething, M.-J. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19471 · Cited by 83
Akakura, S., Yoshida, M., Yoneda, Y., & Horinouchi, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100200200 · Cited by 64
Temperature sensitivity for conformation is an intrinsic property of wild-type p53
Hainaut, P. L., Butcher, S., & Milner, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.48 · Cited by 49
Harper, J. W. (2004) · Cell · doi:10.1016/j.cell.2004.06.015 · Cited by 45
Hsp70 binds specifically to a peptide derived from the highly conserved domain (I) region of P53
Lam, K. T., & Calderwood, S. K. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91174-o · Cited by 37
Burch, L. R., Shimizu, H., Smith, A. J., Patterson, C., & Hupp, T. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.01.017 · Cited by 36
Exploiting the p53 pathway for cancer diagnosis and therapy
Woods, Y. L., & Lane, D. P. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200260 · Cited by 28
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
The role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
Metadata
- Authors
- Esser, C., Scheffner, M., & Höhfeld, J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2005-07
- Volume
- 280
- Issue
- 29
- Pages
- 27443-27448
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2038449857
- Cited by
- 261
- References
- 67
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.